In Silico Evaluation of an Artificial Pancreas Combining Exogenous Ultrafast-Acting Technosphere Insulin with Zone Model Predictive Control
Компьютерная оценка искусственной поджелудочной железы, сочетающей экзогенный ультрабыстродействующий инсулин Technosphere с зональным модельно-прогнозирующим управлением
2013-01-01
SCID: 54.1/axy5ww5z
Discuss with AI
Artificial pancreasIn silico metabolic simulatorPostprandial hyperglycemiaTechnosphere InsulinZone model predictive control
Figures from the paper
Abstract (AI)
BACKGROUND: Because of the slow pharmacokinetics of subcutaneous (SC) insulin, avoiding postprandial hyperglycemia has been a major challenge for an artificial pancreas (AP) using SC insulin without a meal announcement. METHODS: A semiautomated AP with Technosphere® Insulin (TI; MannKind Corporation, Valencia, CA) was designed to combine pulmonary and SC insulin. Manual inhalation of 10 U ultrafast-absorbing TI at mealtime delivers the first, or cephalic, phase of insulin, and an SC insulin pump controlled by zone model predictive controller delivers second-phase and basal insulin. This AP design was evaluated on 100 in silico subjects from the University of Virginia/Padova metabolic simulator using a protocol of two 50 g carbohydrate (CHO) meals and two 15 g CHO snacks. RESULTS: Simulation analysis shows that the semiautomated AP with TI provides 32% and 16% more time in the controller target zone (80-140 mg/dl) during the 4 h postprandial period, with 39 and 20 mg/dl lower postprandial blood glucose peak on average than the pure feedback AP and the AP with manual feed-forward SC bolus, respectively. No severe hypoglycemia (<50 mg/dl) was observed in any cases. CONCLUSIONS: The semiautomated AP with TI provides maximum time in the clinically accepted region when compared with pure feedback AP and AP with manual feed-forward SC bolus. Furthermore, the semiautomated AP with TI provides a flexible operation (optional TI inhalation) with minimal user interaction, where the controller design can be tailored to specific user needs and abilities to interact with the device.
Key Findings
1
A semiautomated artificial pancreas combines mealtime inhaled ultrafast Technosphere Insulin with pump-delivered subcutaneous insulin controlled by zone model predictive control.
2
Average postprandial glucose peaks were 39 mg/dl lower than with pure feedback control and 20 mg/dl lower than with manual feed-forward subcutaneous boluses.
3
In 100 in silico subjects, the combined system increased postprandial time in the 80–140 mg/dl target zone by 32% versus pure feedback control and 16% versus manual feed-forward subcutaneous bolus control.
4
No severe hypoglycemia below 50 mg/dl occurred in any simulated case.
5
Optional Technosphere Insulin inhalation enables flexible operation with minimal user interaction and allows controller tailoring to user needs and abilities.
Research Object
A semiautomated artificial pancreas combining exogenous ultrafast-acting Technosphere Insulin inhalation with a subcutaneous insulin pump
Research Subject
Postprandial glycemic control performance, including time in the target glucose zone, blood-glucose peaks, and hypoglycemia risk, under zone model predictive control
Publication Details
Publication Date
2013-01-01
Journal
Journal of Diabetes Science and Technology
Publisher
SAGE Publishing
ISSN
1932-2968
Cited by
18
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest